NUTX · Nutex Health Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $216.49M | - | $267.80M | $243.99M | $211.79M | - | $78.79M | $76.08M | $67.45M | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | $91.73M | - | $154.88M | $124.92M | $118.34M | - | $21.92M | $22.56M | $10.16M | - |
| R&D | - | - | - | - | - | - | - | - | - | - |
| SG&A | $14.38M | - | $11.30M | $12.50M | $10.04M | - | $9.87M | $10.65M | $8.66M | - |
| Total Operating Expenses | $10.46M | - | $24.51M | $91.25M | $46.13M | - | $12.25M | $17.26M | $8.71M | - |
| D&A | $5.49M | - | $5.00M | $5.25M | $5.09M | - | $4.97M | $4.53M | $4.19M | - |
| Operating Income | $81.27M | - | $130.37M | $33.68M | $72.21M | - | $9.66M | $5.30M | $1.45M | - |
| Interest Expense | $4.68M | - | $5.45M | $5.68M | $4.44M | - | $4.10M | $5.05M | $4.44M | - |
| Income Tax | $13.80M | - | $27.14M | $7.59M | $18.54M | - | $4.58M | $893.9K | $389.7K | - |
| Net Income | $46.81M | - | $55.44M | ($17.70M) | $14.63M | - | ($8.79M) | ($364.0K) | ($364.1K) | - |
| EPS - Basic | $6.70 | - | $8.27 | ($2.95) | $2.65 | - | ($1.72) | ($0.07) | ($0.10) | - |
| EPS - Diluted | $6.52 | - | $7.76 | ($2.95) | $2.56 | - | ($1.72) | ($0.07) | ($0.10) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $207.35M | $185.57M | $166.05M | $96.73M | $87.67M | $43.58M | $46.91M | $40.81M | $30.01M | $22.00M |
| Accounts Receivable | - | - | - | - | $295.08M | $232.45M | $62.75M | $60.66M | $61.53M | $58.62M |
| Inventory | $4.68M | $2.87M | $3.16M | $2.27M | $3.12M | $2.85M | $2.26M | $2.76M | $2.98M | $3.39M |
| Accounts Payable | - | - | - | - | $19.84M | $9.61M | $10.32M | $16.74M | $17.22M | $18.90M |
| Current Assets | $579.65M | $538.81M | $592.65M | $473.02M | $401.52M | $292.48M | $119.80M | $113.87M | $100.36M | $90.85M |
| Total Assets | $957.32M | $918.52M | $964.52M | $841.03M | $761.92M | $655.32M | $438.49M | $422.40M | $404.28M | $398.25M |
| Current Liabilities | $184.44M | $157.91M | $185.46M | $194.87M | $176.57M | $140.87M | $67.56M | $71.66M | $59.89M | $58.31M |
| Long-term Debt | $24.26M | $29.17M | $25.57M | $20.46M | $21.73M | $22.47M | $26.80M | $22.41M | $26.31M | $26.31M |
| Total Liabilities | $515.26M | $495.09M | $526.49M | $504.15M | $487.04M | $453.43M | $358.71M | $340.38M | $324.27M | $319.14M |
| Stockholders' Equity | $346.29M | $329.45M | $317.17M | $235.25M | $197.11M | $146.34M | $60.44M | $62.73M | $63.02M | $61.45M |
| Retained Earnings | ($239.38M) | ($286.19M) | ($298.02M) | ($353.46M) | ($342.26M) | ($356.89M) | ($418.59M) | ($409.80M) | ($409.44M) | ($409.07M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $75.52M | - | - | - | $50.97M | - | - | - | $3.05M | - |
| Investing Cash Flow | ($1.20M) | - | - | - | ($64.0K) | - | - | - | ($733.3K) | - |
| Financing Cash Flow | ($49.55M) | - | - | - | ($6.81M) | - | - | - | $5.69M | - |
| CapEx | $1.20M | - | - | - | $733.0K | - | - | - | - | - |
| Free Cash Flow | $74.32M | - | - | - | $50.23M | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 42.4% | - | 57.8% | 51.2% | 55.9% | - | 27.8% | 29.7% | 15.1% | - |
| Operating margin | 37.5% | - | 48.7% | 13.8% | 34.1% | - | 12.3% | 7.0% | 2.1% | - |
| EBITDA margin | 40.1% | - | 50.5% | 16.0% | 36.5% | - | 18.6% | 12.9% | 8.4% | - |
| Net margin | 21.6% | - | 20.7% | -7.3% | 6.9% | - | -11.2% | -0.5% | -0.5% | - |
| Free cash flow margin | 34.3% | - | - | - | 23.7% | - | - | - | - | - |
| FCF / Net income | 1.59 | - | - | - | 3.43 | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | 6.6% | - | 4.2% | 5.1% | 4.7% | - | 12.5% | 14.0% | 12.8% | - |
| Effective tax rate | 22.8% | - | 32.9% | - | 55.9% | - | - | 168.7% | 1522.7% | - |
| Return on assets | 4.9% | - | 5.7% | -2.1% | 1.9% | - | -2.0% | -0.1% | -0.1% | - |
| Return on equity | 13.5% | - | 17.5% | -7.5% | 7.4% | - | -14.5% | -0.6% | -0.6% | - |
| Return on invested capital | 16.9% | - | 25.5% | 10.4% | 16.5% | - | 8.7% | 3.1% | 0.8% | - |
| Liquidity | ||||||||||
| Current ratio | 3.14 | 3.41 | 3.20 | 2.43 | 2.27 | 2.08 | 1.77 | 1.59 | 1.68 | 1.56 |
| Quick ratio | 3.12 | 3.39 | 3.18 | 2.42 | 2.26 | 2.06 | 1.74 | 1.55 | 1.63 | 1.50 |
| Cash ratio | 1.12 | 1.18 | 0.90 | 0.50 | 0.50 | 0.31 | 0.69 | 0.57 | 0.50 | 0.38 |
| Leverage | ||||||||||
| Debt / Equity | 0.07 | 0.09 | 0.08 | 0.09 | 0.11 | 0.15 | 0.44 | 0.36 | 0.42 | 0.43 |
| Debt / Assets | 0.03 | 0.03 | 0.03 | 0.02 | 0.03 | 0.03 | 0.06 | 0.05 | 0.07 | 0.07 |
| Debt / EBITDA | 0.28 | - | 0.19 | 0.53 | 0.28 | - | 1.83 | 2.28 | 4.67 | - |
| Interest coverage | 17.4x | - | 23.9x | 5.9x | 16.2x | - | 2.4x | 1.0x | 0.3x | - |
| Equity multiplier | 2.76 | 2.79 | 3.04 | 3.58 | 3.87 | 4.48 | 7.25 | 6.73 | 6.42 | 6.48 |
| Liabilities / Assets | 0.54 | 0.54 | 0.55 | 0.60 | 0.64 | 0.69 | 0.82 | 0.81 | 0.80 | 0.80 |
| Efficiency | ||||||||||
| Asset turnover | 0.23 | - | 0.28 | 0.29 | 0.28 | - | 0.18 | 0.18 | 0.17 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | 509d | - | 291d | 291d | 333d | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | 14.6x | - | 13.3x | - | 18.4x | - | - | - | - | - |
| P / B | 2.0x | - | 1.7x | 3.2x | 1.2x | - | 1.6x | - | 9.9x | - |
| P / S | 3.2x | - | 2.0x | 3.1x | 1.1x | - | 1.2x | - | 9.3x | - |
| EV / EBITDA | 5.8x | - | 2.9x | 17.2x | 2.1x | - | 5.2x | - | 110.2x | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 2.2% | - | 239.9% | 220.7% | 214.0% | - | 25.6% | 29.1% | 19.7% | - |
| Revenue CAGR (3y) | 56.6% | - | 109.8% | 61.4% | 224.3% | - | 141.9% | 143.2% | 222.3% | - |
| Revenue CAGR (5y) | 154.8% | - | 277.3% | 264.6% | 240.1% | - | 536.4% | 555.2% | 561.5% | - |
| Gross profit growth (YoY) | -22.5% | - | 606.7% | 453.7% | 1065.1% | - | 210.2% | 133.9% | 109.5% | - |
| Operating income growth (YoY) | 12.5% | - | 1249.2% | 535.6% | 4881.3% | - | - | - | - | - |
| Net income growth (YoY) | 219.9% | - | - | -4761.2% | - | - | -58.6% | 89.5% | 92.9% | - |
| EPS growth (YoY) | 154.7% | - | - | -4114.3% | - | - | -17100.0% | -600.0% | - | - |
| EPS CAGR (3y) | 446.3% | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | 47.9% | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 75.7% | 125.1% | 424.8% | 275.0% | 212.8% | 138.1% | -32.8% | -32.3% | -32.0% | -35.9% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$877.75M totalHospital Division$844.16M · 96.2%
Population Health Management Division$31.09M · 3.5%
Real Estate Division$2.49M · 0.3%
Product / service
$875.26M totalHospital Division$844.16M · 96.4%
Population Health Management Division$31.09M · 3.6%
Peer comparison
Same SIC group: Services-Business Services, NEC
Comparing Nutex Health Inc. against the 5 most active filers in the same SIC group.